Recent 8-K filings for RGBP

• July 15, 2026, 4:18 PM ET litigation materiality 0.80 negative item 1.01item 8.01item 9.01

  Regen Biopharma settles $398,740 claims via share issuance; creates Series N preferred with 75M votes per share

  Court approved settlement with Trillium Partners: Regen will issue shares (common or Series A preferred) to satisfy $398,740 in claims; shares sold by plaintiff, 65% of net proceeds to plaintiff.

• March 4, 2026, 6:59 PM ET other material materiality 0.75 negative item 3.02 ◈ Equity Issuances

  Regen Biopharma issues 77.85M shares to settle $68,723 in debt and fees

  Issued 77,849,847 common shares between Feb 4-27, 2026 for $53,474 principal, $4,249 interest, $11,000 fees.

• February 2, 2026, 6:59 PM ET other material materiality 0.85 negative item 3.02 ◈ Equity Issuances ×3

  Regen Biopharma issues 21.4M shares in Jan 2026 for $69,550, massive dilution

  On Jan 15, 2026, issued 5,000,000 shares to satisfy $11,449 principal + $8,101 interest on convertible debt.

• October 3, 2025, 7:59 PM ET other material materiality 0.75 negative item 1.01item 8.01item 9.01

  Regen BioPharma issues 40M shares to CEO and consultant for Phase I trial; shares vest on trial success

  Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.

• August 1, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 3.02item 9.01

  Regen Biopharma enters $130K convertible note financing with CFI Capital

  Issued a 6% convertible promissory note for $130,000 principal; $13,000 original issue discount, net proceeds $117,000.

• June 11, 2025, 7:59 PM ET other material materiality 0.70 neutral item 3.02item 9.01

  Regen Biopharma issues 10M shares to CEO in settlement of $50K accrued salary

  Issued 10,000,000 common shares to CEO David R. Koos as settlement for $50,000 of accrued unpaid salary.

• May 13, 2025, 7:59 PM ET other material materiality 0.70 negative item 4.02 ◈ Auditor Changes

  Regen Biopharma restates FY2024 financials; prior statements not reliable

  Non-reliance on unaudited FY2024 financials filed Nov 20, 2024; share compensation and derivative liability corrected.

• April 7, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01 ◈ Auditor Changes ×2

  Regen Biopharma dismisses Bush & Associates, engages BCRG Group as new auditor

  Dismissed Bush and Associates CPA LLC as independent auditor effective March 31, 2025.

• November 29, 2024, 6:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716

  Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.

• September 13, 2024, 7:59 PM ET debt materiality 0.65 negative item 1.01item 9.01

  Regen Biopharma issues $250K promissory note to Coventry; $25K OID, convertible on default

  Principal amount $250K; original issue discount $25K, net proceeds $200K.

• May 10, 2024, 7:59 PM ET other material materiality 0.60 negative item 4.01 ◈ Auditor Changes

  Regen Biopharma dismisses auditor BF Borgers due to SEC cease-and-desist order

  BF Borgers CPA PC dismissed as independent auditor effective May 10, 2024, following SEC order of May 3, 2024.

• March 21, 2023, 7:59 PM ET other material materiality 0.60 negative item 3.02item 3.03

  Regen Biopharma issues 15K Series NC preferred shares to CEO with super-voting rights

  Issued 15,000 Series NC preferred shares to CEO David Koos to settle $10,050 debt.

• February 7, 2023, 6:59 PM ET other material materiality 0.60 negative item 5.03 ◈ Governance Changes ×3

  Regen Biopharma files 1-for-1500 reverse stock split and reduces preferred voting power

  Series AA preferred votes reduced to 7 per share; Series NC to 334 per share, effective March 6, 2023.

• November 18, 2022, 6:59 PM ET other material materiality 0.70 neutral item 3.02

  Regen Biopharma issues 101.9M Series A Preferred and 16.9M common shares in debt-for-equity swap

  Issued 101,880,008 shares of Series A Preferred to satisfy $511,500 convertible debt and $253,816 accrued interest.

• July 20, 2022, 7:59 PM ET debt materiality 0.60 neutral item 3.02

  Regen Biopharma issues 54.5M shares to retire $180,552 convertible note with Coventry

  Issued 54,514,492 common shares to Coventry Enterprises LLC to satisfy $180,552 of convertible indebtedness.

• May 17, 2022, 7:59 PM ET other material materiality 0.65 neutral item 3.02item 8.01

  Regen Biopharma issues 100M shares to settle debt; subsidiary gets NR2F6 patent

  Issued 100M common shares to Coventry Enterprises LLC to satisfy $334,800 of convertible debt; note balance now $648,001.

• February 18, 2022, 6:59 PM ET other material materiality 0.60 negative item 8.01

  Regen Biopharma terminates acquisition negotiations for Canary Oncoceutics stake

  Terminated all negotiations to acquire 95% of Canary Oncoceutics.

• December 22, 2021, 6:59 PM ET other material materiality 0.80 negative item 4.02

  Regen Biopharma restates June 30, 2021 financials; $1.9M revenue incorrectly recognized

  Board concluded Q2 and nine-month FY2021 financials should no longer be relied upon.

• November 12, 2021, 6:59 PM ET M&A materiality 0.70 neutral item 8.01

  Regen Biopharma signs non-binding LOI to acquire 95% of Canary Oncoceutics for $1M cash and stock

  Consideration: $1,000,000 cash plus common shares valued at RGBP's average share price pre-closing.

• November 5, 2021, 7:59 PM ET debt materiality 0.70 neutral item 8.01

  Regen Biopharma reduces convertible note principal by $967,830 via equity and cash

  Satisfied $967,830 of principal and $539,392 in fees/interest through 706M common shares, 23.7M Series A preferred, and $218,529 cash.

• November 4, 2021, 7:59 PM ET other material materiality 0.60 positive item 8.01

  Regen Biopharma awarded USPTO patent for NR2F6-silenced cord blood killer cell cancer therapy

  USPTO issued Patent No. 11,141,471 on Oct 12, 2021, covering universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells.

• October 22, 2021, 7:59 PM ET other material materiality 0.85 positive item 8.01

  Regen BioPharma settles convertible notes for $43,529 cash to avoid potential issuance of 855M shares

  Settled convertible notes principal of $29,836 and accrued interest of $26,227 for $43,529.30 cash.

• September 27, 2021, 7:59 PM ET other material materiality 0.60 positive item 8.01

  Regen Biopharma receives USPTO Notice of Allowance for NR2F6 activity modulators patent

  Notice of Allowance issued Sept 23, 2021 for patent on small molecule agonists/antagonists of NR2F6.

• September 24, 2021, 7:59 PM ET debt materiality 0.75 positive item 1.01item 8.01item 9.01

  Regen Biopharma secures $1.39M net financing via $1.5M note, settles ChemDiv lawsuit for $800K

  Issued $1.5M promissory note to Coventry Enterprises LLC; net proceeds $1.39M after $75K OID and $35K fees.

• September 16, 2021, 7:59 PM ET litigation materiality 0.60 neutral item 1.01item 9.01

  Regen Biopharma settles ChemDiv lawsuit for $800k, contingent on SEC filing by Sept 24

  Regen to pay $800k lump sum by Sept 30, 2021, to settle ChemDiv's breach-of-contract lawsuit over ~$1.2M unpaid invoices.

• July 2, 2021, 7:59 PM ET other material materiality 0.65 positive item 8.01

  Regen Biopharma subsidiary KCL receives USPTO patent grant for NR2F6 inhibition cancer therapy

  KCL Therapeutics (Regen Biopharma subsidiary) granted USPTO patent for NR2F6 inhibition method.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

10 positive 14 negative 25 neutral

source · RGBP on sec.gov